Ascendis Pharma A/S (ASND) Stock Price, News & Analysis

Company Overview

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S. Food and Drug Administration for the treatment of pediatric growth hormone deficiency. By transiently conjugating active hormone to a carrier molecule, the TransCon platform allows controlled release of the therapeutic agent over time, reducing injection frequency and helping to maintain more consistent drug exposure.

Beyond growth hormone deficiency, Ascendis Pharma is advancing a pipeline of product candidates aimed at other rare endocrine disorders. TransCon parathyroid hormone (PTH) is in clinical development for hypoparathyroidism and has demonstrated positive proof‐of‐concept data. The company is also investigating TransCon CNP for the treatment of achondroplasia, a form of dwarfism, and pursuing additional indications in both endocrine and broader metabolic diseases.

Ascendis Pharma’s management team brings together experienced professionals in drug development, regulatory affairs and commercial strategy. The company continues to expand its global footprint through strategic collaborations and partnerships, with the goal of delivering transformative therapies to patients with underserved conditions.

Key Stats

• Today's Range: $191.19 to $194.75
• 50-Day Range: $163.32 to $198.32
• 52-Week Range: $111.09 to $199.99
• Volume: 357,323 shs
• Average Volume: 548,125 shs
• Market Capitalization: $11.89 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $243.36
• Consensus Rating: Buy

Ascendis Pharma A/S Stock Analysis - MarketRank™

Ascendis Pharma A/S scored higher than 67% of companies evaluated by MarketBeat, and ranked 329th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Ascendis Pharma A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 15 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Ascendis Pharma A/S has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($4.34) to $0.24 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ascendis Pharma A/S is -37.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ascendis Pharma A/S is -37.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.52% of the float of Ascendis Pharma A/S has been sold short.

Short Interest Ratio / Days to Cover

Ascendis Pharma A/S has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Ascendis Pharma A/S has recently increased by 1.10%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ascendis Pharma A/S does not currently pay a dividend.

Dividend Growth

Ascendis Pharma A/S does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.52% of the float of Ascendis Pharma A/S has been sold short.

Short Interest Ratio / Days to Cover

Ascendis Pharma A/S has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Ascendis Pharma A/S has recently increased by 1.10%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 1.51

News Sentiment

Ascendis Pharma A/S has a news sentiment score of 1.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.09 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Ascendis Pharma A/S this week, compared to 8 articles on an average week.

Search Interest

10 people have searched for ASND on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

6 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.

ASND Stock Analysis - Frequently Asked Questions

How have ASND shares performed this year?

Ascendis Pharma A/S's stock was trading at $137.67 on January 1st, 2025. Since then, ASND stock has increased by 41.1% and is now trading at $194.27.

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) posted its quarterly earnings data on Thursday, August, 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating analysts' consensus estimates of ($1.42) by $0.49. The biotechnology company earned $216.28 million during the quarter, compared to the consensus estimate of $163.17 million.
Read the conference call transcript.

When did Ascendis Pharma A/S IPO?

Ascendis Pharma A/S (ASND) raised $85 million in an initial public offering (IPO) on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's top institutional investors include Westfield Capital Management Co. LP (8.91%), Artisan Partners Limited Partnership (6.53%), Massachusetts Financial Services Co. MA (3.11%) and Perceptive Advisors LLC (1.58%).

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ascendis Pharma A/S investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 8/31/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ASND
• CIK: 1612042
• Web: www.ascendispharma.com
• Phone: (457) 022-2244
• Fax: 45-3694-4010
• Employees: 1,017
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Ascendis Pharma A/S: $243.36
• High Price Target: $307.00
• Low Price Target: $153.00
• Potential Upside/Downside: +25.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$409.12 million
• Net Margins: -54.94%
• Pretax Margin: -53.33%
• Return on Equity: N/A
• Return on Assets: -24.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.02
• Quick Ratio: 0.69

Sales & Book Value

• Annual Sales: $490.75 million
• Price / Sales: 24.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.48) per share
• Price / Book: -55.82

Miscellaneous

• Outstanding Shares: 61,211,000
• Free Float: 36,727,000
• Market Cap: $11.89 billion
• Optionable: Optionable
• Beta: 0.41